May 15: Early-Stage Health Technology Assessment (HTA) - In Person at ISPOR 2022
1:00PM-5:00PM Eastern Daylight Time (EDT)
As the cost of bringing a new health technology to market continues to climb, more and more firms, developers, and investors are searching for tools to prioritize their efforts on the technologies with the greatest potential for clinical impact and market viability. While health economic analysis has long been established as a necessity to inform decision making for market access and reimbursement, it is increasingly being used at earlier stages of product development for healthcare and life sciences to increase the access rate of R&E and efficiently prioritize data collection. The number of available methods for this field has continued to expand.
This course aims to demystify the objectives of early-stage health technology assessment and the methods of translational health economics. Students in the course will gain a thorough understanding of available methods for early-stage technology assessment, the specific challenges and solutions, and a clear sense of how to implement this in the complexity of health technology development, funding, regulation, pricing, and reimbursement. The course will utilize real-world examples and students will have the opportunity to strategize about the creation of a research plan for their purposes.
***Registrants will receive a digital course book. Copyright, Trademark and Confidentiality Policies apply.***
May 15, 2022
Back to all short courses
Early-Stage Health Technology Assessment (HTA)
LEVEL: Introductory
TRACK: Health Technology Assessment
LENGTH: 4 Hours | Course runs 1 day
This short course will be offered in-person at the ISPOR 2022 conference. Separate registration is required. Visit the ISPOR 2022 website to register and learn more.
1:00PM-5:00PM Eastern Daylight Time (EDT)
DESCRIPTION
As the cost of bringing a new health technology to market continues to climb, more and more firms, developers, and investors are searching for tools to prioritize their efforts on the technologies with the greatest potential for clinical impact and market viability. While health economic analysis has long been established as a necessity to inform decision making for market access and reimbursement, it is increasingly being used at earlier stages of product development for healthcare and life sciences to increase the access rate of R&E and efficiently prioritize data collection. The number of available methods for this field has continued to expand.This course aims to demystify the objectives of early-stage health technology assessment and the methods of translational health economics. Students in the course will gain a thorough understanding of available methods for early-stage technology assessment, the specific challenges and solutions, and a clear sense of how to implement this in the complexity of health technology development, funding, regulation, pricing, and reimbursement. The course will utilize real-world examples and students will have the opportunity to strategize about the creation of a research plan for their purposes.
***Registrants will receive a digital course book. Copyright, Trademark and Confidentiality Policies apply.***
FACULTY MEMBERS
Lotte Steuten, MSc, PhD
Office of Health Economics
London, UK
William Canestaro, PhD
Washington Research Foundation
Seattle, WA, USA
Erik Landaas, PhD, MPH
Cook Medical
Bloomington, IN, USA
Basic Schedule:
4 Hours | Course runs 1 Day